BACKGROUND: Research has established the societal cost-effectiveness of providing breast and cervical cancer screening to women. Less is known about the cost of motivating women significantly overdue for services to receive screening. METHODS: In this intent-to-treat study, a total of 254 women, aged 52-69, who were overdue for both Pap test and mammography, were randomized to two groups, a tailored, motivational outreach or usual care. For effectiveness, we calculated the percent of women who received both services within 14 months of randomization. We used a comprehensive cost model to estimate total cost, per-participant cost, and the incremental cost-effectiveness of delivering the outreach intervention from the health plan perspective. We also conducted sensitivity analyses around two key parameters, target population size and level of effectiveness. RESULTS: Compared with usual care, outreach (P = 0.006) screened significantly more women. The intervention cost US dollars 167.62 (2000 U.S. dollars) for each woman randomized to outreach, and incremental cost-effectiveness of outreach over usual care was US dollars 818 per additional woman screened. Sensitivity analyses estimated incremental cost-effectiveness between Us dollars 19 and US dollars 90 per additional woman screened. CONCLUSIONS: Larger health plans can likely increase Pap test and mammography services in this population for a relatively low cost using this outreach intervention.
RCT Entities:
BACKGROUND: Research has established the societal cost-effectiveness of providing breast and cervical cancer screening to women. Less is known about the cost of motivating women significantly overdue for services to receive screening. METHODS: In this intent-to-treat study, a total of 254 women, aged 52-69, who were overdue for both Pap test and mammography, were randomized to two groups, a tailored, motivational outreach or usual care. For effectiveness, we calculated the percent of women who received both services within 14 months of randomization. We used a comprehensive cost model to estimate total cost, per-participant cost, and the incremental cost-effectiveness of delivering the outreach intervention from the health plan perspective. We also conducted sensitivity analyses around two key parameters, target population size and level of effectiveness. RESULTS: Compared with usual care, outreach (P = 0.006) screened significantly more women. The intervention cost US dollars 167.62 (2000 U.S. dollars) for each woman randomized to outreach, and incremental cost-effectiveness of outreach over usual care was US dollars 818 per additional woman screened. Sensitivity analyses estimated incremental cost-effectiveness between Us dollars 19 and US dollars 90 per additional woman screened. CONCLUSIONS: Larger health plans can likely increase Pap test and mammography services in this population for a relatively low cost using this outreach intervention.
Authors: Frances L Lynch; Ruth H Striegel-Moore; John F Dickerson; Nancy Perrin; Lynn Debar; G Terence Wilson; Helena C Kraemer Journal: J Consult Clin Psychol Date: 2010-06
Authors: Kishore Khankari; Mickey Eder; Chandra Y Osborn; Gregory Makoul; Marla Clayman; Silvia Skripkauskas; Linda Diamond-Shapiro; Dan Makundan; Michael S Wolf Journal: J Gen Intern Med Date: 2007-07-26 Impact factor: 5.128
Authors: Thomas Everett; Andrew Bryant; Michelle F Griffin; Pierre Pl Martin-Hirsch; Carol A Forbes; Ruth G Jepson Journal: Cochrane Database Syst Rev Date: 2011-05-11
Authors: Ytje J J van der Veen; Onno de Zwart; Johan Mackenbach; Jan Hendrik Richardus Journal: BMC Public Health Date: 2010-11-05 Impact factor: 3.295
Authors: Mary E Costanza; Roger Luckmann; Mary Jo White; Milagros C Rosal; Caroline Cranos; George Reed; Robin Clark; Susan Sama; Robert Yood Journal: BMC Health Serv Res Date: 2011-06-03 Impact factor: 2.655
Authors: David R Lairson; Tong Han Chung; Danmeng Huang; Timothy E Stump; Patrick O Monahan; Shannon M Christy; Susan M Rawl; Victoria L Champion Journal: Cancer Prev Res (Phila) Date: 2020-01-22